Compare AIBZ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIBZ | ACIU |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Canada | Switzerland |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 247.6M |
| IPO Year | 2026 | 2015 |
| Metric | AIBZ | ACIU |
|---|---|---|
| Price | $4.16 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.57 |
| AVG Volume (30 Days) | ★ 308.7K | 146.7K |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $422.39 |
| Revenue Next Year | N/A | $377.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $2.10 |
| 52 Week High | $9.91 | $4.00 |
| Indicator | AIBZ | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.96 |
| Support Level | N/A | $2.58 |
| Resistance Level | N/A | $2.68 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 49.81 |
Bitzero Holdings Inc is a provider of IT energy infrastructure and high-efficiency power for data centers. It focuses on data center development, Bitcoin mining, and obtaining strategic data center hosting partnerships. The company has four data center locations in the North American and Scandinavian regions, powered by clean, low-carbon energy sources. The company is driven by experience in infrastructure and a passion for positive change to become the international leader in Blockchain mining and HPC hosting in a sustainable fashion that emphasizes the long-term value proposition for all stakeholders.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.